A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue which comprises an insulin sensitizer an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided. In an embodiment there is provided a solid preparation comprising a layer containing pioglitazone or a salt thereof; and a layer containing glimepiride and a polyoxyethylene sorbitan fatty acid ester.

Pharmaceutical composition comprising an insulin sensitivity enhancer such as pioglitazone or pharmaceutically acceptable salt thereof in combination with insulin secretion enhancer selected from glibenclamide and glimepiride and use thereof for the manufacture of a medicament for the treatment or prophylaxis of diabetes or diabetic complications.

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

A preparation for treating diabetes comprises pioglitazone hydrochloride glimepiride and Polysorbate 80.

A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue which comprises an insulin sensitizer an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided.